Dr. Sabbatini on Novel Approaches With IP Therapy For Ovarian Cancer

Paul Sabbatini, MD
Published: Wednesday, Nov 29, 2017



Paul Sabbatini, MD, deputy physician-in-chief for clinical research, Memorial Sloan Kettering Cancer Center, discusses novel approaches for IP therapy for patients with ovarian cancer.

Dose-dense therapy or every-3-week therapy allows for many additional combinations in the primary setting, explains Sabbatini. Adding PARP inhibitors, maintenance therapy, anti-vascular agents, or other novel compounds are currently being investigated.

According to Sabbatini, it would be difficult to incorporate those into an IP with cisplatin.
 


Paul Sabbatini, MD, deputy physician-in-chief for clinical research, Memorial Sloan Kettering Cancer Center, discusses novel approaches for IP therapy for patients with ovarian cancer.

Dose-dense therapy or every-3-week therapy allows for many additional combinations in the primary setting, explains Sabbatini. Adding PARP inhibitors, maintenance therapy, anti-vascular agents, or other novel compounds are currently being investigated.

According to Sabbatini, it would be difficult to incorporate those into an IP with cisplatin.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian CancerOct 31, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x